Starting April 10, CivicaScript will offer its new drug, droxidopa, for $2,100 less than the average monthly price paid by a Medicare Part D beneficiary.
CivicaScript members, which include more than a dozen Blue Cross Blue Shield companies, said droxidopa is “a priority generic medicine based on its high list price from other manufacturers and significant patient need for the product,” according to a news release.
The capsules are “indicated for the treatment of orthostatic dizziness, lightheadedness, or the ‘feeling that you are about to black out’ in adult patients with symptomatic neurogenic orthostatic hypotension,” according to its label.
The company manufactures 100 milligram, 200 milligram and 300 milligram presentations of droxidopa capsules. A 90-capsule bottle at the 300 mg dose is available to pharmacies for $132, and CivicaScript recommends a maximum retail price of $153 per bottle.
CivicaScript — which manufactures and distributes low-cost, outpatient generic medications — is a sister company to Civica Inc. (Civica Rx). Health systems formed Civica in 2018 to address rising costs and chronic supply shortages in the generics market.
After launching its first drug, a prostate cancer therapy, in 2022, Gina Guinasso, then president of CivicaScript, told Becker’s the company was working on offering six to 10 more discounted generics over the next few years.
